Update on third-generation EGFR tyrosine kinase inhibitors

被引：7
|
作者：
Gray, Jhanelle
Haura, Eric
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol & Chem Biol, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Program Mol Med, Tampa, FL 33612 USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2014年 / 3卷 / 06期
关键词：
D O I：
10.3978/j.issn.2218-6751.2014.09.08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 362
页数：3
相关论文
共 50 条
  • [21] AURORA KINASE A IS RESPONSIBLE OF RESISTANCE TO THIRD-GENERATION ANTI-EGFR INHIBITORS IN LUNG CANCER
    不详
    ESMO OPEN, 2019, 4 (01)
  • [22] A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors
    Mitsuya, S.
    Tsuruoka, K.
    Kanaoka, K.
    Funamoto, T.
    Tsuji, H.
    Matsunaga, N.
    Nakamura, T.
    Tamura, Y.
    Imanishi, M.
    Ikeda, S.
    Fujisaka, Y.
    Goto, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S596 - S596
  • [23] Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC
    Park, Ha-Ram
    Kim, Tae Min
    Lee, Yusoo
    Kim, Soyeon
    Park, Seongyeol
    Ju, Young Seok
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1859 - 1871
  • [24] Emerging strategies to overcome resistance to third-generation EGFR inhibitors
    Kunyu Shi
    Guan Wang
    Junping Pei
    Jifa Zhang
    Jiaxing Wang
    Liang Ouyang
    Yuxi Wang
    Weimin Li
    Journal of Hematology & Oncology, 15
  • [25] Emerging strategies to overcome resistance to third-generation EGFR inhibitors
    Shi, Kunyu
    Wang, Guan
    Pei, Junping
    Zhang, Jifa
    Wang, Jiaxing
    Ouyang, Liang
    Wang, Yuxi
    Li, Weimin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [26] Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Alissa J. Cooper
    Lecia V. Sequist
    Jessica J. Lin
    Nature Reviews Clinical Oncology, 2022, 19 : 499 - 514
  • [27] Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Cooper, Alissa J.
    Sequist, Lecia, V
    Lin, Jessica J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (08) : 499 - 514
  • [28] Therapeutic potential of ERK inhibitors in overcoming acquired resistance to third generation EGFR tyrosine kinase inhibitors
    Li, Yiting
    Qian, Guoqing
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    CANCER RESEARCH, 2019, 79 (13)
  • [29] First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
    Tatineni, Vineeth
    O'Shea, Patrick J.
    Ozair, Ahmad
    Khosla, Atulya A.
    Saxena, Shreya
    Rauf, Yasmeen
    Jia, Xuefei
    Murphy, Erin S.
    Chao, Samuel T.
    Suh, John H.
    Peereboom, David M.
    Ahluwalia, Manmeet S.
    CANCERS, 2023, 15 (08)
  • [30] New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer
    Fassunke, J.
    Heydt, C.
    Michels, S.
    Van Veggel, B.
    Mueller, F.
    Keul, M.
    Dammert, M. A.
    Schmitt, A.
    Smit, E. F.
    Kast, S.
    Wolf, J.
    Buettner, R.
    Sos, M. L.
    Rauh, D.
    Merkelbach-Bruse, S.
    ANNALS OF ONCOLOGY, 2019, 30
12345